UTMD

Business Context and Reporting Period

Company: Utah Medical Products Inc. (UTMD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: UTMD manufactures and markets specialty medical devices, including the Filshie Clip System, neonatal monitoring, and biopharmaceutical pressure monitoring components. The company operates as a single segment with manufacturing and sales in the U.S., Ireland, UK, Australia, Canada, and France.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Q2 2025 sales decreased 4.3% year-over-year (YoY), while 1H 2025 sales dropped 9.6% YoY. The decline is primarily attributed to a significant reduction in sales to a major OEM customer, PendoTECH, which represented 71% of the Q2 decline and 86% of the 1H decline.
• Margin Compression: Gross margins contracted from 60.1% to 56.2% in Q2 due to lower sales volume in Ireland (reducing fixed cost absorption), unfavorable product mix, and higher raw material costs. U.S. margins remained consistent.
• Expense Reduction: Operating expenses decreased significantly due to lower U.S. litigation costs ($355k lower in Q2, $791k lower in 1H). This offset some of the gross profit decline, keeping operating margins relatively stable.
• Share Count Reduction: The company repurchased 119,255 shares in 1H 2025 for $6.7 million. This reduction in share count mitigated the decline in EPS, which fell 4.0% in Q2 compared to an 11.7% drop in Net Income.
• Foreign Currency Impact: A stronger USD against the EUR and GBP provided a favorable translation impact of $173k in Q2 sales, though constant currency sales were down 21.4% in Q2.

Guidance, Outlook, and Risks

• Outlook: Management expects 2H 2025 sales to PendoTECH to be approximately $200k lower than 2H 2024, resulting in a full-year 2025 sales decline of roughly $2 million compared to 2024. The company aims to maintain strong financial performance despite revenue contraction.
• Tariff Risks: Potential "reciprocal tariffs" imposed by foreign governments on U.S.-affiliated entities pose a risk to OUS sales. A major distributor in China has requested delaying a $800k shipment due to tariff uncertainty, which could further reduce 2025 revenue and impact Ireland's gross margins.
• Legal Proceedings: Filshie clip product liability lawsuits remain in discovery. Management does not expect the outcome to be material to consolidated financial results.
• Capital Allocation: The company continues to return capital to shareholders via dividends ($0.305/share in Q2) and opportunistic share repurchases. No new employee stock options were awarded in 2025.
• EBITDA Target: Management's beginning-of-year target for Adjusted Consolidated EBITDA of $17-$18 million remains achievable, with TTM EBITDA at $18.7 million as of June 30, 2025.

Investor Verification Checklist

• PendoTECH Exposure: Verify the sustainability of the remaining $264k in 1H 2025 sales to PendoTECH and the accuracy of the projected $2 million full-year decline.
• Tariff Impact on China: Monitor the status of the delayed $800k shipment to the Chinese distributor and assess the likelihood of reciprocal tariffs affecting other OUS markets.
• Ireland Operations: Review the specific product mix shifts in Ireland that led to margin compression and assess if fixed cost absorption issues are structural or temporary.
• Share Repurchase Strategy: Confirm the company's continued commitment to repurchasing shares given the current cash balance of $82.2 million and the lack of a formal plan limit.
• Intangible Asset Amortization: Note that the Femcare IIA amortization expense (approx. $2M/year) will be fully amortized in Q1 2026, which will significantly boost future operating income.